amyloid-based therapies did fail again! it is the right time to change our vision on building block of alzheimer's disease.

Amyloid-based therapies did fail again! It is the right time to change our vision on building block of Alzheimer's disease

Alois Alzheimer, the Bavarian neuropathologist, first introduced the Alzheimer's disease (AD) in 1906 following detection of amyloid plaques, neurofibrillary tangles, and arteriosclerotic changes in the brain of his patient. AD is known as the most frequent global form of dementia, these days, representing 50-80% of all cases1 with huge patient maintenance costs (i.e. 172 billion US dollars in ...

HIV result giving. Is it time to change our thinking?

BACKGROUND Ensuring patients receive post-test discussion when collecting HIV test results is an integral component of the HIV testing process. New South Wales Health Department (NSW Health) policy recommends that all patients be given their HIV results in person. We assessed the number of patients who returned for HIV test results to Royal Prince Alfred Sexual Health Clinic in Sydney, Australi...

Permissive hypoxemia: is it time to change our approach?

Ahmed et al1 reported an interesting case of Wegener granulomatosis with diffuse alveolar hemorrhage in a 26-year-old woman. The patient was urgently intubated, sedated, paralyzed, and maintained on 100% oxygen and a positive end-expiratory pressure as high as 18 cm H2O. Despite the use of different modes of ventilation, including volume control, pressure control with inverse inspiratory/expira...

robotic anesthesia: how is it going to change our practice?

Is it time to combine osteoporosis therapies?

www.thelancet.com Published online May 15, 2013 http://dx.doi.org/10.1016/S0140-6736(13)60984-8 1 Some therapies licensed to treat osteoporosis work by inhibiting bone turnover (anticatabolic agents) and some by stimulating bone formation (anabolic agents). In The Lancet, Joy Tsai and colleagues report an exciting new approach in which an anticatabolic drug, denosumab, is combined with an anabo...

Replication Licensing: Oops! … I Did It Again

All eukaryotes use multiple controls to restrict DNA replication to once per cell cycle. Nevertheless, inactivation of a single gene, cul-4, causes massive re-replication in Caenorhabditis elegans. A novel study explains this dramatic phenotype by demonstrating that the CUL-4 E3 ligase simultaneously controls two critical licensing factors: CDT-1 and CDC-6.